Janux Therapeutics, Inc. (NASDAQ: JANX) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.
| Index | - | P/E | - | EPS (ttm) | -1.64 | Insider Own | - | Shs Outstand | 60.98M | Perf Week | -4.64% |
| Market Cap | 1.03B | Forward P/E | - | EPS next Y | -2.67 | Insider Trans | -0.02% | Shs Float | 57.09M | Perf Month | -0.59% |
| Enterprise Value | 75.20M | PEG | - | EPS next Q | -0.45 | Inst Own | - | Short Float | 10.62% | Perf Quarter | 19.15% |
| Income | -102.00M | P/S | 32.13 | EPS this Y | -6.45% | Inst Trans | - | Short Ratio | 6.22 | Perf Half Y | 21.65% |
| Sales | 32.00M | P/B | 1.11 | EPS next Y | -53.18% | ROA | -10.18% | Short Interest | 6.06M | Perf YTD | 22.17% |
| Book/sh | 15.22 | P/C | 1.06 | EPS next 5Y | - | ROE | -10.79% | 52W High | 35.34 -52.29% | Perf Year | -27.98% |
| Cash/sh | 15.92 | P/FCF | - | EPS past 3/5Y | - | ROIC | -15.11% | 52W Low | 12.12 39.11% | Perf 3Y | 64.33% |
| Dividend Est. | - | EV/EBITDA | - | Sales past 3/5Y | 3.57% - | Gross Margin | 68.91% | Volatility | 4.26% 4.27% | Perf 5Y | -40.99% |
| Dividend TTM | - | EV/Sales | 2.35 | EPS Y/Y TTM | -28.12% | Oper. Margin | -450.30% | ATR (14) | 0.79 | Perf 10Y | - |
| Dividend Ex-Date | - | Quick Ratio | 16.35 | Sales Y/Y TTM | 190.91% | Profit Margin | -321.81% | RSI (14) | 44.24 | Recom | 2.31 |
| Dividend Gr. 3/5Y | - | Current Ratio | 16.35 | EPS Q/Q | 36.36% | SMA20 | -7.75% | Beta | 2.38 | Target Price | 28.25 |
| Payout | 0.00% | Debt/Eq | 0.02 | Sales Q/Q | - | SMA50 | -0.31% | Rel Volume | 0.80 | Prev Close | 16.25 |
| Employees | 113 | LT Debt/Eq | 0.02 | Earnings | Nov 05 | SMA200 | 12.13% | Avg Volume | 1.01M | Price | 16.86 |
| IPO Date | Jun 11, 2021 | Option/Short | Yes / Yes | EPS/Sales Surpr. | -39.28% -46.17% | Net Debt/EBITDA | 0.07 | Volume | 810,005 | Change | 3.75% |
| Date | Action | Analyst | Rating | Target |
|---|---|---|---|---|
| Aug-24-26 | Upgrade | Wolfe Research | Peer Perform → Outperform | $23 |
| Aug-07-26 | Reiterated | Stifel Nicolaus | $38 → $35 | |
| Aug-07-26 | Reiterated | Guggenheim | Buy | $55 |
| Jun-25-26 | Reiterated | Truist Financial | $26 | |
| May-11-26 | Reiterated | Evercore ISI | $23 → $22 | |
| May-08-26 | Reiterated | Wedbush | Outperform | $36 |
| Apr-20-26 | Downgrade | Barclays | Overweight → Underweight | $29 → $14 |
| Apr-15-26 | Downgrade | UBS | Buy → Neutral | $57 → $15 |
| Jan-20-26 | Downgrade | Clear Street | Buy → Hold | |
| Jan-16-26 | Reiterated | Piper Sandler | Overweight | $30 |
Janux Therapeutics, Inc. is a biopharmaceutical company dedicated to developing innovative cancer therapies. The firm leverages its proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to create treatments designed to activate the body's T cells to fight tumors. Currently, Janux has several promising TRACTr product candidates in their early preclinical or discovery stages, which are engineered to target specific antigens such as prostate-specific membrane antigen, epidermal growth factor receptor, and trophoblast cell surface antigen 2. In addition to its TRACTr pipeline, the company is also developing a Tumor Activated Immunomodulator (TRACIr) — a costimulatory bispecific candidate designed to enhance T cell anti-tumor activity by engaging with programmed death-ligand 1 and CD28. Furthermore, a specific focus for their EGFR-TRACTr program is addressing epidermal growth factor receptor, a target prevalent in many cancer types and already a focus of numerous approved monoclonal antibody treatments. Janux Therapeutics, Inc. was founded in 2017 and is headquartered in La Jolla, California.
Per-holder 13F data hasn't been ingested for this ticker yet.
| Line Item (USD, M) | TTM — | FY 2025 12/31/2025 | FY 2024 12/31/2024 | FY 2023 12/31/2023 | FY 2022 12/31/2022 | FY 2021 12/31/2021 | FY 2020 12/31/2020 | FY 2019 12/31/2019 | |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | 32 | 10 | 11 | — | — | — | — | — | |
| Cost of Goods Sold Incl. D&A | 10 | 2 | 2 | — | — | — | — | — | |
| Gross Profit | 21 | 8 | 9 | — | — | — | — | — | |
| Selling, General and Administrative Excl. Other | 43 | 42 | 41 | — | — | — | — | — | |
| Research and Development | 125 | 126 | 68 | — | — | — | — | — | |
| Other Operating Expense | -3 | -2 | -2 | — | — | — | — | — | |
| Operating Income | -143 | -158 | -99 | — | — | — | — | — | |
| Interest Expense | 0 | 0 | 0 | — | — | — | — | — | |
| Unusual Expense | — | — | — | — | — | — | — | — | |
| Non-Operating Income (Expense) | 41 | 44 | 30 | — | — | — | — | — | |
| Net Income Before Taxes | -102 | -114 | -69 | — | — | — | — | — | |
| Income Taxes | 0 | 0 | 0 | — | — | — | — | — | |
| Consolidated Net Income | -102 | -114 | -69 | — | — | — | — | — | |
| Net Income From Continuing Operations | -102 | -114 | -69 | — | — | — | — | — | |
| Net Income | -102 | -114 | -69 | — | — | — | — | — | |
| EPS (Recurring) | -1.64 | -1.83 | -1.28 | — | — | — | — | — | |
| EPS (Basic, Before Extraordinaries) | -1.64 | -1.83 | -1.28 | — | — | — | — | — | |
| EPS (Diluted) | -1.64 | -1.83 | -1.28 | — | — | — | — | — | |
| EBITDA | -101 | -112 | -67 | — | — | — | — | — | |
| Other After Tax Adjustments | — | — | — | — | — | — | — | — | |
| Stock Option Compensation Expense | — | — | — | — | — | — | — | — | |
| Price To Earnings Ratio | — | — | — | — | — | — | — | — | |
| Price To Sales Ratio | 33.19 | 85.56 | 262.83 | — | — | — | — | — | |
| Gross Margin | 65.63 | 80.00 | 81.82 | — | — | — | — | — | |
| Operating Margin | -446.88 | -1,580.00 | -900.00 | — | — | — | — | — | |
| Net Margin | -318.75 | -1,140.00 | -627.27 | — | — | — | — | — | |
| Shares Outstanding | 63 | 62 | 54 | — | — | — | — | — | |
| Market Capitalization | 1,062 | 856 | 2,891 | — | — | — | — | — | |
| Operating Lease Expense | — | — | — | — | — | — | — | — |
| Insider | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|
| Campbell David Alan | President and CEO | Jul 08 '26 | Option Exercise | 4.21 | 7,000 | 29,470 | 388,582 | Jul 10 |
| Doyle Janeen Noel | Chief Corp. & Bus. Dev. Ofcr | Jun 02 '26 | Sale | 14.03 | 4,059 | 56,944 | 75,941 | Jun 04 |
| Dobek Maria | Vice President, Accounting | May 11 '26 | Sale | 14.17 | 2,038 | 28,878 | 32,270 | May 13 |
| Meyer Andrew Hollman | Chief Business Officer | Jan 02 '26 | Sale | 13.73 | 1,879 | 25,799 | 83,095 | Jan 02 |
| DiRaimondo Thomas | Chief Scientific Officer | Jan 02 '26 | Sale | 13.73 | 2,505 | 34,394 | 124,425 | Jan 02 |
| Campbell David Alan | President and CEO | Jan 02 '26 | Sale | 13.73 | 8,072 | 110,829 | 284,982 | Jan 02 |
| Winter Charles M. | Chief Technical Officer | Jan 02 '26 | Sale | 13.73 | 2,401 | 32,966 | 77,721 | Jan 02 |
| McIver Zachariah | Chief Medical Officer | Jan 02 '26 | Sale | 13.73 | 2,714 | 37,263 | 23,286 | Jan 02 |
| Dobek Maria | Vice President, Accounting | Jan 02 '26 | Sale | 13.73 | 1,462 | 20,073 | 15,373 | Jan 02 |
| Meyer Andrew Hollman | Chief Business Officer | Dec 01 '25 | Option Exercise | 10.59 | 3,333 | 35,296 | 88,307 | Dec 03 |
| Meyer Andrew Hollman | Chief Business Officer | Dec 01 '25 | Sale | 32.98 | 3,333 | 109,929 | 84,974 | Dec 03 |
| Meyer Andrew Hollman | Chief Business Officer | Nov 14 '25 | Option Exercise | 10.59 | 3,333 | 35,296 | 88,307 | Nov 14 |
| Meyer Andrew Hollman | Chief Business Officer | Nov 14 '25 | Sale | 30.00 | 3,333 | 99,990 | 84,974 | Nov 14 |
| Meyer Andrew Hollman | Chief Business Officer | Oct 28 '25 | Option Exercise | 6.76 | 16,665 | 112,689 | 98,804 | Oct 30 |
| Meyer Andrew Hollman | Chief Business Officer | Oct 28 '25 | Sale | 30.06 | 16,665 | 500,987 | 82,139 | Oct 30 |